ESC 365 - The effect of DOAC-Stop on lupus anticoagulant testing in patients with pulmonary embolism receiving direct oral anticoagulants

ESC Professional Premium Access

The effect of DOAC-Stop on lupus anticoagulant testing in patients with pulmonary embolism receiving direct oral anticoagulants

Session: Oral anticoagulation in patients with venous thromboembolism or left ventricular thrombus

Topic: Anticoagulants

Speaker: Professor A. Undas (Krakow, PL)

Event: ESC Congress 2023

Congress Presentation

About the speaker

Professor Anetta Undas

Jagiellonian University, Krakow (Poland)

0 follower

6 more presentations in this session

Baseline characteristics and outcomes of extended oral anticoagulant treatment in patients with venous thrombosis: a retrospective cohort study in France

Speaker: Mr R. Subash (Surrey, GB)

Comparative effectiveness and safety of apixaban and low-molecular weight heparin among patients with venous thromboembolism and active cancer in an extended treatment setting

Speaker: Doctor A. Cohen (London, GB)

Anticoagulant therapy beyond primary treatment among active cancer and non-cancer patients with venous thromboembolism in the United States

Speaker: Doctor A. Cohen (London, GB)

Clinical characteristics and outcomes of super-low-dose edoxaban of 15 mg in patients with acute venous thromboembolism: insight from the COMMAND VTE Registry-2

Speaker: Doctor K. Kaneda (Kyoto, JP)

Predicting thrombus outcome during anticoagulation for left ventricular thrombus

Speaker: Doctor Q. Yang (Beijing, CN)

Access the full session

Oral anticoagulation in patients with venous thromboembolism or left ventricular thrombus

Speakers: Professor A. Undas, Mr R. Subash, Doctor A. Cohen, Doctor A. Cohen, Doctor K. Kaneda...

About the event

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress

ESC 365 is supported by